# Innate Pharma (IPHA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IPHA
## Company Profile
- Ticker: IPHA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: France
- Tags: Oncology
## Stock Data
- Close: 1.77 USD
- Market cap: 170903984.16 USD
- Last updated: 2026-08-05
## Business Overview
### Innate Immunity Oncology Company
Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer.
### Lacutamab
Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma.
### ADC and Partnered Pipeline
IPH4502 is a Nectin-4 ADC, while partnered programs include monalizumab and anti-CD39 antibody IPH5201 with AstraZeneca.
## Why The Stock Is Moving

As of Aug 5, 2026, IPHA closed down 0.84% at $1.77. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the confirmatory Phase 3 TELLOMAK-3 study of lacutamab is planned for the second half of 2026, subject to securing non-dilutive financing.
- Phase 3 PACIFIC-9 data for the monalizumab-containing regimen are planned for the second half of 2026.

## Drug Assets

- IPH4502

## Recent News
- 2026-07-22 11:17 EST — [Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/IPHA/innate-pharma-to-participate-in-a-bladder-cancer-panel-at-the-btig-virtual-biote-960627c0) — Source: Innate Pharma
- 2026-07-20 14:53 EST — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) — Source: Innate Pharma
- 2026-05-21 17:08 EST — [Outcome of Innate Pharma’s 2026 Annual General Meeting](https://biopharmsignal.com/news/IPHA/outcome-of-innate-pharma-s-2026-annual-general-meeting) — Source: Innate Pharma
- 2026-05-18 11:27 EST — [Innate Pharma to participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/IPHA/innate-pharma-to-participate-in-the-jefferies-global-healthcare-conference) — Source: Innate Pharma
- 2026-05-12 13:48 EST — [Innate Pharma Reports First Quarter 2026 Business Update and Financial Results](https://biopharmsignal.com/news/IPHA/innate-pharma-reports-first-quarter-2026-business-update-and-financial-results) — Source: Innate Pharma